The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI

被引：1

作者：

Carbonara, Sergio ^{[1
]}

机构：

[1] Osped Vittorio Emanuele II, Units Operativa Complessa Malattie Infett, Bisceglie, Italy

来源：

GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT | 2024年 / 11卷

关键词：

ABSSSI; Dalbavancin; Dehospitalization; Infection management; Healthcare costs; ACUTE BACTERIAL SKIN; STRUCTURE INFECTIONS; THERAPY; EXPERIENCE; SAFETY;

D O I：

10.33393/grhta.2024.3045

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Acute bacterial skin and skin structure infections (ABSSSIs) represent a common and costly healthcare burden, accounting for millions of annual infections and billions of dollars in healthcare expenditures. Dalbavancin is a long-acting glycopeptide antibiotic that has demonstrated efficacy and safety in the treatment of ABSSSIs. This review article will examine the efficacy of dalbavancin and focus on its impact on the hospital length of stay and costs associated with management of these infections.

引用

页码：13 / 17

页数：5

共 28 条

[1] Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis [J].

Agarwal, R. ;

Bartsch, S. M. ;

Kelly, B. J. ;

Prewitt, M. ;

Liu, Y. ;

Chen, Y. ;

Umscheid, C. A. .

CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (04) :361-368

[2]

[Anonymous], 2022, Hospital adjusted expenses per inpatient day

[3] Effectiveness, safety and cost analysis of dalbavancin in clinical practice [J].

Arrieta-Loitegui, Maria ;

Manuel Caro-Teller, Jose ;

Ortiz-Perez, Sara ;

Lopez-Medrano, Francisco ;

San Juan-Garrido, Rafael ;

Miguel Ferrari-Piquero, Jose .

EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (01) :55-58

[4] Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals [J].

Bai, Francesca ;

Mazzitelli, Maria ;

Silvola, Sofia ;

Raumer, Francesca ;

Restelli, Umberto ;

Croce, Davide ;

Marchetti, Giulia ;

Cattelan, Anna Maria .

JAC-ANTIMICROBIAL RESISTANCE, 2023, 5 (02)

[5]

Bosso John A, 2016, Hosp Pract (1995), V44, P183, DOI 10.1080/21548331.2016.1230466

[6] Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection [J].

Boucher, Helen W. ;

Wilcox, Mark ;

Talbot, George H. ;

Puttagunta, Sailaja ;

Das, Anita F. ;

Dunne, Michael W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (23) :2169-2179

[7] Dalbavancin in the treatment of different gram-positive infections: a real-life experience [J].

Bouza, Emilio ;

Valerio, Maricela ;

Soriano, Alex ;

Morata, Laura ;

Garcia Carus, Enrique ;

Rodriguez-Gonzalez, Carmen ;

Hidalgo-Tenorio, Ma Carmen ;

Plata, Antonio ;

Munoz, Patricia ;

Vena, Antonio .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 51 (04) :571-577

[8] Real world utilization of Dalbavancin at a rural community emergency department [J].

Dolan, Alex ;

Kuge, Elizabeth ;

Bremmer, Elisha ;

Dietrich, Tyson ;

Santarelli, Anthony ;

Ashurst, John .

AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2022, 54 :253-256

[9] A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection [J].

Dunne, Michael W. ;

Puttagunta, Sailaja ;

Giordano, Philip ;

Krievins, Dainis ;

Zelasky, Michael ;

Baldassarre, James .

CLINICAL INFECTIOUS DISEASES, 2016, 62 (05) :545-551

[10] Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies [J].

Dunne, Michael W. ;

Talbot, George H. ;

Boucher, Helen W. ;

Wilcox, Mark ;

Puttagunta, Sailaja .

DRUG SAFETY, 2016, 39 (02) :147-157

← 1 2 3 →